Welcome to our dedicated page for Surrozen news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.
Surrozen Inc (SRZN) is a clinical-stage biotechnology company pioneering regenerative therapies through targeted modulation of the Wnt signaling pathway. This page provides investors and researchers with timely updates on the company’s progress in developing treatments for severe liver diseases and retinal disorders.
Access official press releases, clinical trial announcements, and research milestones related to Surrozen’s proprietary platforms, including SWEETS and SWAP. Stay informed about regulatory developments, partnership agreements, and scientific breakthroughs in tissue-specific antibody therapies.
Our curated news collection serves as a neutral, comprehensive resource for tracking Surrozen’s advancements in early-phase trials and preclinical research. Bookmark this page for streamlined access to verified updates about the company’s innovative approach to activating the body’s natural repair mechanisms.
Surrozen presented preliminary Phase 1a study results of their novel drug SZN-043 at the 2024 European Association for the Study of the Liver (EASL) conference in Milan. This study involved 40 healthy volunteers and 8 liver cirrhosis patients, focusing on dose safety and tolerance. SZN-043 showed potential in increasing Wnt signaling and hepatocyte proliferation, with pharmacodynamic biomarkers confirming target engagement. Mild, transient serum transaminase elevations were noted but resolved without intervention. Current enrollment is ongoing for a Phase 1b study targeting severe alcohol-associated hepatitis, aiming to optimize Wnt pathway modulation for liver regeneration.
Surrozen has dosed its first patient in a Phase 1b clinical trial for SZN-043, a bispecific fusion protein targeting ASGR1, aimed at treating severe alcohol-associated hepatitis. This open-label, multi-center trial will involve around 30 patients and assess safety, pharmacokinetics, immunogenicity, and efficacy endpoints like MELD and Lille scores, which are linked to clinical improvement and survival.
CEO Craig Parker highlighted the company's progress and expects proof-of-concept data by the first half of 2025. Previous Phase 1a data indicated SZN-043's safety, tolerability, and beneficial effects on liver function. The trial addresses a significant unmet need, as severe alcohol-associated hepatitis has had no survival improvements for over 50 years.
Surrozen presented data at the ARVO Annual Meeting showcasing the potential of their antibody-based Wnt mimetic technologies in treating cornea endothelial dystrophies and Dry Eye Disease. The preclinical studies demonstrated significant improvements in corneal edema, endothelial cell proliferation, and tear volume production utilizing Surrozen's SWAP technologies. These findings offer hope for patients suffering from these severe eye diseases.
Surrozen, Inc. provided its first quarter 2024 financial results and business updates, focusing on advancing the SZN-043 Phase 1b trial for severe alcohol-associated hepatitis. The company presented promising preclinical data for eye and lung diseases, and highlighted a partnership with Boehringer Ingelheim for retinal disease treatment. Financially, while cash and cash equivalents decreased, a recent financing round boosted proforma cash. Research and development expenses decreased, along with general and administrative expenses, showcasing a strategic focus on clinical programs.
FAQ
What is the current stock price of Surrozen (SRZN)?
What is the market cap of Surrozen (SRZN)?
